In 2014 the fixed dose combination drug sofosbuvir/ledipasvir, the latter a viral NS5A inhibitor, was approved; it had also been granted breakthrough status.
Pada tahun 2014, obat kombinasi berdosis tetap sofosbuvir/ledipasvir, yang terakhir adalah inhibitor NS5A virus, disetujui; juga diberikan gelar terobosan.